Edition:
United States

Depomed Inc (DEPO.OQ)

DEPO.OQ on NASDAQ Stock Exchange Global Select Market

16.47USD
17 Feb 2017
Change (% chg)

$-0.38 (-2.26%)
Prev Close
$16.85
Open
$16.79
Day's High
$16.79
Day's Low
$16.31
Volume
358,801
Avg. Vol
410,497
52-wk High
$27.00
52-wk Low
$12.25

DEPO.OQ

Chart for DEPO.OQ

About

Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company's products include NUCYNTA ER (tapentadol extended release tablets), which is a product for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment,... (more)

Overall

Beta: 1.28
Market Cap(Mil.): $1,014.23
Shares Outstanding(Mil.): 61.58
Dividend: --
Yield (%): --

Financials

  DEPO.OQ Industry Sector
P/E (TTM): -- 28.47 29.39
EPS (TTM): -1.23 -- --
ROI: -6.77 13.57 13.06
ROE: -23.73 14.45 14.19

RPT-Starboard Value up more than 10 pct, led by Depomed stake -document

NEW YORK, Nov 16 Starboard Value, the activist hedge fund behind shake-ups at Yahoo Inc and Marvell Technology Group Ltd, has notched an investment return of more than 10 percent this year on the back of boardroom deals and takeovers.

Nov 17 2016

Starboard Value up more than 10 percent, led by Depomed stake: document

NEW YORK Starboard Value, the activist hedge fund behind shake-ups at Yahoo Inc and Marvell Technology Group Ltd , has notched an investment return of more than 10 percent this year on the back of boardroom deals and takeovers.

Nov 16 2016

Starboard Value up more than 10 pct, led by Depomed stake -document

NEW YORK, Nov 16 Starboard Value, the activist hedge fund behind shake-ups at Yahoo Inc and Marvell Technology Group Ltd, has notched an investment return of more than 10 percent this year on the back of boardroom deals and takeovers.

Nov 16 2016

BRIEF-Depomed Q3 loss per share $0.21

* Q3 earnings per share view $0.35 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Nov 07 2016

Depomed agrees temporary truce with Starboard in proxy fight

Depomed Inc on Monday reached a deal with activist investor Starboard Value LP to avoid a shareholder vote due next month to oust the drugmaker's entire board.

Oct 17 2016

UPDATE 1-Depomed agrees temporary truce with Starboard in proxy fight

Oct 17 Depomed Inc on Monday reached a deal with activist investor Starboard Value LP to avoid a shareholder vote due next month to oust the drugmaker's entire board.

Oct 17 2016

Starboard drops its bid to oust Depomed's board

Oct 17 Depomed Inc said activist investor Starboard Value LP, which owns 9.8 percent of the drugmaker, had dropped its bid to oust the company's board.

Oct 17 2016

BRIEF-Depomed and Starboard announce settlement agreement

* Depomed says in connection with entering into agreement, board amended company's bylaws

Oct 17 2016

Depomed wins Nucynta patent dispute; may spur sale talks

A court ruled in Depomed Inc's favor in a patent dispute over its opioid drug, Nucynta, a decision that could help pave the way for the drug maker to explore a sale.

Sep 30 2016

Depomed wins Nucynta patent dispute; may spur sale talks

A court ruled in Depomed Inc's favor in a patent dispute over its opioid drug, Nucynta, a decision that could help pave the way for the drug maker to explore a sale.

Sep 30 2016

More From Around the Web

Earnings vs. Estimates